Nothing Special   »   [go: up one dir, main page]

CO6140038A2 - Metodos y estuches para administracion de probioticos - Google Patents

Metodos y estuches para administracion de probioticos

Info

Publication number
CO6140038A2
CO6140038A2 CO09101613A CO09101613A CO6140038A2 CO 6140038 A2 CO6140038 A2 CO 6140038A2 CO 09101613 A CO09101613 A CO 09101613A CO 09101613 A CO09101613 A CO 09101613A CO 6140038 A2 CO6140038 A2 CO 6140038A2
Authority
CO
Colombia
Prior art keywords
loading
probiotic
dose
during
administer
Prior art date
Application number
CO09101613A
Other languages
English (en)
Inventor
Susan Louise Abeln
Duane Larry Charbonneau
Ker-Sang Chen
James Patrick Ebel
Mary Elaine Freeland
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO6140038A2 publication Critical patent/CO6140038A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/133—Fruit or vegetables
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)

Abstract

Se describen métodos para administrar probióticos; los métodos comprenden los pasos de: administrar una dosis de carga de un probiótico de carga durante un período de carga; y administrar una dosis de una planta medicinal y/o materiales adicionales durante el período de carga. Los métodos también incluyen administrar una dosis de mantenimiento de un probiótico de mantenimiento y/o una planta medicinal y/o un material adicional durante un periodo de mantenimiento. También se describen estuches para usarse en la administración de probióticos. 1.- Un método para administrar un probiótico; el método comprende los pasos de: a. administrar una dosis de carga de un probiótico de carga durante un período de carga; y b. administrar una dosis de una planta medicinal durante el período de carga.2.- El método de conformidad con la reivindicación 1, que además comprende administrar un material adicional.3.- El método de conformidad con la reivindicación 1, caracterizado además porque el probiótico de carga comprende bacterias acidolácticas seleccionadas del grupo consistente de Bifidobacterium, Lactobacillus, Streptococcus y combinaciones de éstas.4.- El método de conformidad con la reivindicación 3, caracterizado además porque las bacterias acidolácticas comprenden una cepa aislada de Bifidobacterium infantis.5.- El método de conformidad con la reivindicación 1, caracterizado además porque el probiótico de carga se administra para suministrar de aproximadamente 1 x 103 a aproximadamente 1 x 1014 ufc de probiótico de carga por día.
CO09101613A 2007-03-27 2009-09-18 Metodos y estuches para administracion de probioticos CO6140038A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92017707P 2007-03-27 2007-03-27

Publications (1)

Publication Number Publication Date
CO6140038A2 true CO6140038A2 (es) 2010-03-19

Family

ID=39769593

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09101613A CO6140038A2 (es) 2007-03-27 2009-09-18 Metodos y estuches para administracion de probioticos

Country Status (13)

Country Link
US (1) US20080241226A1 (es)
EP (1) EP2129385A2 (es)
JP (1) JP2010522246A (es)
KR (1) KR20090109131A (es)
CN (1) CN101636173A (es)
AU (1) AU2008230747A1 (es)
BR (1) BRPI0809454A2 (es)
CA (1) CA2682763A1 (es)
CO (1) CO6140038A2 (es)
MX (1) MX2009010187A (es)
RU (1) RU2009133376A (es)
WO (1) WO2008119012A2 (es)
ZA (1) ZA200905886B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192733B2 (en) * 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
JP4938005B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティックであるラクトバシラス
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
WO2009158384A1 (en) * 2008-06-27 2009-12-30 The Procter & Gamble Company Methods and kits for the treatment inhibition, and maintenance of gastrointestinal disorders
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
US9649380B2 (en) 2009-01-12 2017-05-16 Pfizer Italia S.R.L. Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin
US20100330151A1 (en) * 2009-06-25 2010-12-30 Mary Elaine Freeland Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate
US20110014324A1 (en) * 2009-07-10 2011-01-20 Christoffer Lundqvist Product for the storage of freeze-dried lactic acid bacteria mixed with oral rehydration solution
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8617536B2 (en) 2009-10-30 2013-12-31 Mayo Foundation For Medical Education And Research Prevotella histicola preparations and the treatment of autoimmune conditions
EP2332426A1 (en) * 2009-12-11 2011-06-15 Technische Universität Graz Prebiotic
KR101143997B1 (ko) * 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
US8946153B2 (en) * 2010-03-29 2015-02-03 Ferring B.V. Fast dissolving pharmaceutical composition
FI20105670A (fi) * 2010-06-11 2011-12-12 Suomen Punainen Risti Veripalvelu ABO-tyypin käyttö
US9301973B2 (en) 2010-10-27 2016-04-05 Nestec S.A. Methods and compositions suitable for promoting healthy skin
PT2481299T (pt) * 2011-01-31 2017-03-08 Synformulas Gmbh Estirpes de bifidobacterium bifidum para aplicação em doenças gastrointestinais
US20120230957A1 (en) * 2011-03-09 2012-09-13 Northwestern University Compositions and methods for treatment of pain
JP2013119546A (ja) * 2011-12-09 2013-06-17 Meiji Co Ltd 不安及び／又は多動性の改善剤
AT512342B1 (de) 2011-12-19 2013-10-15 Sciotec Diagnostic Technologies Gmbh Zusammensetzung
EP2914136B1 (en) * 2012-11-02 2021-05-26 N.V. Nutricia Synbiotics combination for brain improvement
CN105188400B (zh) 2013-03-15 2024-04-05 马斯公司 用于预防、减轻、缓解或治疗特发性呕吐的组合物和方法
CN105209053A (zh) 2013-03-15 2015-12-30 爱默思公司 用于预防、减轻、缓解或治疗特发性呕吐的组合物和方法
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
CA2927360C (en) 2013-10-25 2023-04-18 Nch Corporation Delivery system and probiotic composition for animals and plants
WO2015134808A2 (en) * 2014-03-06 2015-09-11 Research Institute At Nationwide Children's Hospital Probiotic formulations and methods for use
CN104957260B (zh) * 2014-03-07 2018-07-24 内蒙古伊利实业集团股份有限公司 具有缓解咽喉部炎症功效的益生菌食品组合物及食品
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
US10766799B2 (en) 2014-05-23 2020-09-08 Nch Corporation Method for improving quality of aquaculture pond water using a nutrient germinant composition and spore incubation method
KR101971809B1 (ko) * 2014-11-06 2019-04-23 엔더블유오 스템 큐어, 엘엘씨 락토바실러스 람노서스를 보유한 기능식품 보충제
EP3679798B1 (en) 2015-02-03 2021-11-17 Mayo Foundation for Medical Education and Research Methods and materials for assessing and treating arthritis
USD770303S1 (en) 2015-02-03 2016-11-01 Chiasma Inc. Overlay for medication card
US9642773B2 (en) 2015-02-03 2017-05-09 Chiasma Inc. Overlay for medication card
US20160331709A1 (en) * 2015-05-13 2016-11-17 Wow Llc??? Balancing an Unbalanced Sympathetic Nervous System
US10300043B2 (en) 2015-08-12 2019-05-28 Mayo Foundation For Medical Education And Research Method for treating a gastrointestinal disorder in a mammal using bacteroides thetaiotaomicron and compositions thereof
WO2017053544A1 (en) 2015-09-22 2017-03-30 Mayo Foundation For Medical Education And Research Methods and materials for using biomarkers which predict susceptibility to clostridium difficile infection
GB201600975D0 (en) 2016-01-19 2016-03-02 Probi Ab Novel strain of probiotic bacteria and compositions and uses thereof
BR112018014545A2 (pt) 2016-01-19 2018-12-11 Symrise Ag probióticos para uso como agentes anti-inflamatórios na cavidade oral
AU2017240068B2 (en) 2016-03-31 2022-12-15 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
WO2017173241A1 (en) 2016-03-31 2017-10-05 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US12097226B2 (en) 2016-04-05 2024-09-24 Nch Corporation System and method for using a single-serve nutrient spore composition for small scale farm applications
US10897922B2 (en) 2016-04-05 2021-01-26 Nch Corporation Composition and method for germinative compounds in probiotic food and beverage products for human consumption
CA3019732A1 (en) 2016-04-05 2017-10-12 Nch Corporation Nutrient rich germinant composition and spore incubation method
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
WO2017195182A1 (en) * 2016-05-13 2017-11-16 Sofar S.P.A. Use of probiotics for improving protein absorption
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
CN106306284A (zh) * 2016-08-30 2017-01-11 四川高福记生物科技有限公司 一种清除辣火锅痛点的乳酸菌压片糖果及其制备方法
CA3043748A1 (en) 2016-11-23 2018-05-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
WO2019090065A1 (en) * 2017-11-03 2019-05-09 Nch Corporation Composition and method for germinative compounds in probiotic food and beverage products for human consumption
PL3745872T3 (pl) * 2018-01-29 2022-01-31 Precisionbiotics Group Limited Łączony produkt do profilaktyki i leczenia zespołu jelita drażliwego
US11401500B2 (en) 2018-08-29 2022-08-02 Nch Corporation System, method, and composition for incubating spores for use in aquaculture, agriculture, wastewater, and environmental remediation applications
CN109335063A (zh) * 2018-10-17 2019-02-15 西北农林科技大学 一种微生物固体菌剂的包装方式
EP3893674A1 (en) * 2018-12-11 2021-10-20 DSM IP Assets B.V. Use of riboflavin to benefit bowel health
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
WO2021159068A1 (en) 2020-02-06 2021-08-12 Nch Corportion Composition and method of using germinative compounds in probiotics for inflammation reduction in humans
MX2023015531A (es) * 2021-06-21 2024-03-05 Nicoventures Trading Ltd Tableta de producto oral y metodo de fabricacion.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025019A (en) * 1984-04-09 1991-06-18 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4975842A (en) * 1988-08-11 1990-12-04 Schering Corporation Electronic patient diary and patient monitoring process
US7432097B2 (en) * 1997-08-13 2008-10-07 Verenium Corporation Phytases, nucleic acids encoding them and methods of making and using them
WO1999017788A1 (en) * 1997-10-06 1999-04-15 Abbott Laboratories Composition of treatment of candidiasis
US6314405B1 (en) * 1998-07-24 2001-11-06 Donna L. Jung Richardson Medical log apparatus and method
US6080401A (en) * 1998-11-19 2000-06-27 Reddy; Malireddy S. Herbal and pharmaceutical drugs enhanced with probiotics
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
IT1309427B1 (it) * 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
WO2001058465A2 (en) * 2000-02-10 2001-08-16 Gregor Reid Probiotic therapy for newborns
US6579544B1 (en) * 2000-05-31 2003-06-17 Nutriex, L.L.C. Method for supplementing the diet
US20020156640A1 (en) * 2001-04-23 2002-10-24 Hufford Michael R. Instrumentation of a paper diary to create an objective record of events
ITMI20012450A1 (it) * 2001-11-21 2003-05-21 Vito Alloisio Preparazione di grassi alimentari in tubetti
ITMI20020399A1 (it) * 2002-02-28 2003-08-28 Ct Sperimentale Del Latte S P Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici
JP2005139160A (ja) * 2003-03-13 2005-06-02 Kirin Brewery Co Ltd 抗アレルギー用組成物
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
US20050132300A1 (en) * 2003-11-26 2005-06-16 Luhrs Jennifer A. Calendar methods and systems
WO2005085287A1 (en) * 2004-03-03 2005-09-15 En-N-Tech, Inc. Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions
US20070255598A1 (en) * 2006-03-29 2007-11-01 Mccarthy Nancy J Compliance aid, kits comprising the compliance aid, and methods of use

Also Published As

Publication number Publication date
CA2682763A1 (en) 2008-10-02
WO2008119012A3 (en) 2008-11-27
US20080241226A1 (en) 2008-10-02
EP2129385A2 (en) 2009-12-09
BRPI0809454A2 (pt) 2014-09-09
WO2008119012A2 (en) 2008-10-02
ZA200905886B (en) 2010-05-26
AU2008230747A1 (en) 2008-10-02
JP2010522246A (ja) 2010-07-01
KR20090109131A (ko) 2009-10-19
RU2009133376A (ru) 2011-05-10
MX2009010187A (es) 2009-10-19
CN101636173A (zh) 2010-01-27

Similar Documents

Publication Publication Date Title
CO6140038A2 (es) Metodos y estuches para administracion de probioticos
Sieow et al. Tweak to treat: reprograming bacteria for cancer treatment
Chua et al. Designer probiotics for the prevention and treatment of human diseases
Penner et al. Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases
Bui et al. Augmented IFN-γ and TNF-α induced by probiotic bacteria in NK cells mediate differentiation of stem-like tumors leading to inhibition of tumor growth and reduction in inflammatory cytokine release; regulation by IL-10
Rommasi Bacterial-based methods for cancer treatment: What we know and where we are
CN101795693A (zh) 包括施用胆钙化醇的治疗或预防呼吸道感染的方法
RU2013126599A (ru) Нереплицирующиеся пробиотические микроорганизмы, защищающие против инфекций верхних дыхательных путей
WO2019056404A1 (zh) 脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用
AR035761A1 (es) Bacterias de acido lactico como agentes para tratar y prevenir la alergia
Koduganti et al. Probiotics and prebiotics in periodontal therapy
AR054730A1 (es) Nuevas bacterias lacticas utiles como probioticos
AR109085A1 (es) Uso de probióticos en el tratamiento y/o la prevención de la dermatitis atópica
HRPK20130487B3 (hr) Formulacija probiotika s apigeninom i ekstraktom paprene metvice
CN108244655A (zh) 一种安神、抗抑郁的合生元组合物及其制剂与应用
AU2019289119B2 (en) Improving health of the microbiome in a human gastrointestinal system and multi-chamber probiotic delivery products therefor
CN108541951A (zh) 一种预防老年痴呆、增强记忆力的合生元组合物及其制剂
US20160074480A1 (en) Innovative methods of treatmenting tuberculosis
UY32650A (es) Medicamento para la administración oral que contiene al menos un esterógeno y/o al menos un gestágeno y al menos una cepa de bacterias probióticas
MX2013005372A (es) Bacterias probioticas no replicantes y prevencion o tratamiento de infecciones para reducir la inasistencia a la escuela o guarderia.
CN101982180A (zh) 一种新型的益生菌活菌阴道栓体
CL2013002829A1 (es) Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
Borody et al. Therapeutic potential of the human gastrointestinal microbiome
Deb Adhikari et al. Quest for Alternatives to Antibiotics: An Urgent Need of the Twenty-First Century
Suresh et al. Safety concerns of Probiotic use: A review